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OBJECTIVE — To assess the implications of falsely elevated glucose readings measured with
glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) test strips.
RESEARCH DESIGN AND METHODS — We conducted a review of the Food and
Drug Administration’s Manufacturer and User Facility Device Experience database and medical
literature for adverse events (AEs) associated with falsely elevated glucose readings with GDH-
PQQ test strips in the presence of interfering sugars.
RESULTS — Eighty-two reports were identiﬁed: 16 (20%) were associated with death, 46
(56%) with severe hypoglycemia, and 12 (15%) with nonsevere hypoglycemia. In eight reports
(10%), the AE was not described. Forty-two events (51%) occurred in the U.S. Although most
events occurred in hospitalized patients, at least 14 (17%) occurred in outpatients. Agents most
commonly associated with AEs were icodextrin-containing peritoneal dialysate and maltose-
containing intravenous immune globulin.
CONCLUSIONS — GDH-PQQ test strips pose a safety risk to insulin-using patients treated
with agents containing or metabolized to interfering sugars.
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E
nzymesplayacriticalroleinmeasur-
ing blood glucose. Following blood
application, glucose tests strips uti-
lizeenzymestoselectivelycatalyzetheox-
idation of glucose. In many systems, the
product of the enzyme reaction is de-
tected electrochemically, using a meter to
convert the measured current into a glu-
cose value.
Currently available glucose test strip
enzymes include glucose oxidase (GOx),
dehydrogenase (GDH) nicotinamide ade-
nine dinucleotide (GDH-NAD), GDH ﬂa-
vin adenine dinucleotide (GDH-FAD),
and GDH pyrroloquinolinequinone
(GDH-PQQ).GDH-PQQ(referringtona-
tive GDH-PQQ not mutants of GDH-
PQQ) is not glucose speciﬁc. As such, in
additiontoreactingwithglucose,itreacts
withothersugars(maltose,galactose,and
xylose). Systems that utilize GDH-PQQ
test strips may therefore report falsely el-
evated glucose readings in blood samples
frompatientstreatedwithagentscontain-
ing or metabolized to these sugars.
Over the past 10 years, reports have
appeared of GDH-PQQ–related falsely el-
evated glucose readings resulting in insu-
lin overdose and adverse events (AEs),
including severe hypoglycemia and
death. This brief report provides a com-
prehensive assessment of AEs associated
with falsely elevated glucose readings
measured with GDH-PQQ test strips in
the presence of interfering sugars.
RESEARCH DESIGN AND
METHODS— A query of the Food
and Drug Administration’s (FDA’s) Man-
ufacturer and User Facility Device Expe-
rience (MAUDE) database was conducted
in August, 2009. This database contains
voluntary reports since June 1993, user
facility reports since 1991, distributor re-
portssince1993,andmanufacturerreports
sinceAugust1996(availableathttp://www.
fda.gov/cdrh/maude.html). The search was
limited to codes for glucose-monitoring
products and was further limited by
searching for the following key words: mal-
tose, galactose, xylose, icodextrin, extra-
neal, peritoneal dialysis, immunoglobulin,
intravenousimmuneglobulin(IVIG),glob-
ulin, Octagam, Intragam, Gamimune N,
WinRho SDF, HepaGam B, abatacept,
Orencia, Adept Solution, maltodextrin,
galactosemia, tositumomab, and Bexxar.
Eachreportwasassessedbytheauthorsto
identify AEs associated with GDH-PQQ
test strips and an interfering agent or
disorder.
Combinations of the same key words
were used to search Ovid and PubMed
databases for AEs. Each retrieved article
was assessed by the authors, and the arti-
cle’s references were searched for addi-
tional reports. Reports were categorized
by type of AE and agent or condition as-
sociated with the event. AEs appearing in
both MAUDE and literature databases
were counted once.
RESULTS— The MAUDE database
and literature search yielded 61 and 21
unique cases of GDH-PQQ–related AEs,
respectively (see supplementary refer-
ences in the online appendix [available at
http://care.diabetesjournals.org/cgi/content/
full/dc09-1822/DC1]). Table 1 summarizes
the AEs by severity and associated agent
or condition. Of 82 AEs, 16 (20%) were
associated with death and 46 (56%) with
severe hypoglycemia (4 resulting in per-
manent injury). Most events (78%) were
associated with the use of icodextrin-
based peritoneal dialysis (PD) solution
and 13% with a maltose-containing IVIG.
In two reports, the false glucose reading
was associated with galactosemia.
Fifty-nine (72%) events occurred in
an inpatient setting, 14 (17%) in an out-
patient setting, and in 9 (11%) cases the
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events (51%) occurred in the U.S. Other
countries reporting AEs included Austra-
lia,Belgium,China,England,Holland,Is-
rael, Japan, Saudi Arabia, Singapore, and
South Africa.
CONCLUSIONS — Despite repeated
warnings by regulatory agencies and
manufactures, AEs associated with GDH-
PQQ test strips have continued to occur.
A recent FDA Public Health Notiﬁcation
reported 13 deaths associated with GDH-
PQQ test strip interference from nonglu-
cose sugars. Six of 13 deaths occurred
after 2007 (1).
Themostcommonlyimplicatedagent
in our review was icodextrin-containing
PD solution, which is used in treating
end-stagerenaldisease,aconditionwitha
heightened risk of hypoglycemia (2). Im-
portantly, 12% of cases were associated
with maltose-containing IVIG, which is
used in several disorders including pri-
mary immune deﬁciency and idiopathic
thrombocytopenia, and is reportedly
usedofflabel50%ofthetime.Over150
off-label uses were recently described
(3,4). Other maltose-containing agents
that may interfere with GDH-PQQ test
strips include abatacept (for rheumatoid
arthritis), Adept Solution (for reduction
of postsurgical adhesions), and tositu-
momab (for non-Hodgkin’s lymphoma).
Giventhewidespectrumofdisordersthat
may be treated with icodextrin or mal-
tose-containing agents, health care pro-
vidersacrossarangeofspecialtiesneedto
be familiar with this issue.
The majority of AEs in this review
(71%) occurred in an inpatient setting.
Based on similar ﬁndings, the FDA re-
cently issued recommendations to “avoid
using GDH-PQQ glucose test trips in
healthcare facilities” (1). However, 18%
of AEs in our review occurred in an out-
patient setting (including 10 cases of se-
verehypoglycemiaandonedeath).Thisis
not unexpected since PD is primarily ad-
ministered at home and IVIG infusions
may be administered in a provider’s of-
ﬁce. This is therefore an issue that should
be considered for patients in the outpa-
tient setting as well as for hospitalized
patients.
Because voluntary reports in MAUDE
vary in detail and, unlike the published lit-
erature,maynotalwaysprovideenoughin-
formation for the reviewer to establish
directcausality,wechosetoreportallAEsas
device associated. It is important to note
that the AEs summarized in this report
likely represent a small fraction of the AEs
that have actually occurred, as it is well
accepted that signiﬁcant underreporting
of AEs occurs in databases that rely on
spontaneous reporting, including the
FDA’s Adverse Event Reporting System
and MAUDE (5–7).
A list of GDH-PQQ test strips has re-
cently been published (1). The risk posed
by these products must be balanced
against the risk of available alternatives.
Teststripsusingenzymeswithhigherglu-
cose speciﬁcity are widely available.
These include GOx, GDH-NAD, and
GDH-FAD. These enzymes do not yield
falsely elevated glucose readings in the
presence of maltose and galactose (GDH-
FAD does react with xylose). Although
GOx-based test strips can be affected by
varying oxygen levels and may exhibit
chemical interferences common to most
electrochemical systems, these limitations
arenotduetononspeciﬁcityoftheenzyme.
We have found no reports of serious injury
or death due to interferences with GOx,
GDH-NAD, or GDH-FAD enzymes.
Findings in this report indicate that
GDH-PQQ test strips pose an important
safety risk to insulin-treated patients with
diabetes undergoing therapies with agents
containing or metabolized to interfering
sugars. Health care professionals and pa-
tients must be aware of this risk and of
known interfering agents and disorders.
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Type of injury in
AE not reported Total
Icodextrin (PD solution) 10 35 11 8 64
IVIG 3 7 1 0 11
Maltose-containing substance 1 2 0 0 3
Maltodextrin 1 0 0 0 1
Agent not reported 1 0 0 0 1
Galactosemia 0 2 0 0 2
Total 16 46 12 8 82
*Severe hypoglycemia deﬁned as an event requiring assistance of another person to actively administer
carbohydrate, glucagon, or other resuscitative actions.
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